APA (7th ed.) Citation

HIROUCHI, K., KIKUCHI, A., & SATO, M. (2025). USE OF ANTI-CLDN4-ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT.

Chicago Style (17th ed.) Citation

HIROUCHI, Keita, Aya KIKUCHI, and Masahito SATO. USE OF ANTI-CLDN4-ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT. 2025.

MLA (9th ed.) Citation

HIROUCHI, Keita, et al. USE OF ANTI-CLDN4-ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT. 2025.